Suppliers and packagers for FUROSEMIDE

FUROSEMIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Accord Hlthcare	FUROSEMIDE	furosemide	INJECTABLE;INJECTION	070017	ANDA	Accord Healthcare, Inc.	16729-500-08	25 VIAL, SINGLE-DOSE in 1 CARTON (16729-500-08) / 2 mL in 1 VIAL, SINGLE-DOSE (16729-500-30)	2021-05-05
Accord Hlthcare	FUROSEMIDE	furosemide	INJECTABLE;INJECTION	070017	ANDA	Accord Healthcare, Inc.	16729-501-43	10 VIAL, SINGLE-DOSE in 1 CARTON (16729-501-43) / 4 mL in 1 VIAL, SINGLE-DOSE (16729-501-64)	2021-04-21
Accord Hlthcare	FUROSEMIDE	furosemide	INJECTABLE;INJECTION	070017	ANDA	Accord Healthcare, Inc.	16729-502-43	10 VIAL, SINGLE-DOSE in 1 CARTON (16729-502-43) / 10 mL in 1 VIAL, SINGLE-DOSE (16729-502-03)	2021-04-21

Suppliers for the Pharmaceutical Drug: FUROSEMIDE

Last updated: July 28, 2025

Introduction

Furosemide, a potent loop diuretic primarily used to treat edema associated with congestive heart failure, liver cirrhosis, and renal disease, has a critical role in managing fluid overload. As a high-demand therapeutic agent, the landscape of suppliers for furosemide encompasses a diverse array of pharmaceutical manufacturers globally. Understanding the key suppliers, their manufacturing capacities, regulatory statuses, and supply chain dynamics is essential for stakeholders ranging from pharmaceutical companies to healthcare providers.

Global Overview of Furosemide Suppliers

The supply of furosemide is characterized by a mixture of generic drug manufacturers, branded pharmaceutical companies, and contract manufacturing organizations (CMOs). The drug’s manufacturing landscape has evolved significantly over recent decades, reflecting the increasing globalization of the pharmaceutical industry and the prioritization of cost-effective production.

Major Manufacturers and Suppliers

1. Teva Pharmaceuticals

Israel-based Teva Pharmaceuticals is among the largest global producers of generic medicines, including furosemide. The company's extensive manufacturing network spans multiple countries, providing high-volume supply capabilities. Teva’s furosemide products are approved across numerous regions, including the United States, Europe, and Asia, owing to its robust compliance with international quality standards (e.g., FDA, EMA).

2. Sandoz (Novartis)

A leading generics and biosimilars producer, Sandoz maintains a significant portfolio that includes furosemide. Their manufacturing facilities are located across Europe and North America, ensuring a reliable supply chain. Sandoz’s commitment to quality assurance and regulatory compliance solidifies its position as a key player in the furosemide supply chain.

3. Mylan (now part of Viatris)

Viatris, formed by Mylan’s merger with Pfizer’s Upjohn unit, supplies furosemide to various markets. Mylan's manufacturing plants in India, Europe, and North America enable a widespread distribution network, often at competitive prices, thereby increasing access especially in emerging markets.

4. Hikma Pharmaceuticals

Hikma's operations in the Middle East and North Africa (MENA) region, coupled with manufacturing facilities in the UK and the US, make it a significant supplier in both regional and international markets. Hikma’s focus on sterile injectables and oral formulations includes furosemide.

5. Local and Regional Manufacturers

Numerous regional generic manufacturers produce furosemide, especially in Asia (India, China), Latin America, and Eastern Europe. These manufacturers often meet local demand and occasionally export to neighboring regions, although their regulatory approvals may vary.

Contract Manufacturing Organizations (CMOs)

In addition to established pharmaceutical companies, many pharmaceutical firms utilize CMOs to manufacture furosemide. These organizations, including Catalent, Patheon (Thermo Fisher), and Biocon, provide manufacturing services under contract, ensuring scalable production and compliance with Good Manufacturing Practices (GMP).

Manufacturing and Regulatory Considerations

Most of the leading furosemide suppliers operate under stringent regulatory oversight. Their manufacturing facilities are typically inspected and approved by agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other national agencies. Regulatory approval impacts their ability to export and distribute their products internationally.

The complexity of manufacturing furosemide lies in maintaining consistent potency, purity, and stability across batches. Suppliers invest heavily in quality assurance systems, including validated processes and comprehensive quality control protocols.

Supply Chain Dynamics

The supply chain for furosemide is influenced by several factors:

• Raw Material Availability: Furosemide synthesis requires specific chemical intermediates. Disruptions in raw material supply can impact manufacturing output.
• Regulatory Changes: Stringent regulatory standards, especially in developed markets, may impose additional compliance requirements, affecting manufacturing timelines and costs.
• Market Demand Fluctuations: Growing or declining demand influences manufacturing scale and strategic stockpiling.
• Global Events: Pandemics, geopolitical tensions, and trade restrictions could disrupt international supply chains, leading to shortages in critical markets.

Emerging and Future Suppliers

With increasing focus on emerging markets and the ongoing search for cost-effective production, new suppliers are entering the fray. Local pharmaceutical industries in India, China, and Eastern Europe are expanding their manufacturing capacities for furosemide, aiming to meet domestic needs and export demand.

Additionally, advancements in synthetic chemistry and process optimization may facilitate the development of alternative manufacturing routes, potentially impacting the global supplier landscape.

Intellectual Property and Patent Considerations

Furosemide’s original patent expired decades ago, leading to widespread generic production. However, certain formulations or delivery mechanisms might be protected under newer patents, affecting market competition and supplier options in specific regions.

Supply Contract and Licensing Agreements

Major suppliers often engage in licensing agreements, ensuring preferential access and distribution rights across geographic regions. These agreements influence market dynamics, availability, and pricing.

Regulatory Approvals and Quality Standards

Suppliers must secure and maintain approvals from various health authorities. International regulatory harmonization efforts, such as mutual recognition agreements and WHO prequalification, facilitate broader distribution but impose high compliance standards on suppliers.

Consolidation and Industry Trends

The pharmaceutical industry has seen consolidation among generic manufacturers, impacting the supply landscape. Larger entities acquire regional competitors or expand their manufacturing capacities, aiming for economies of scale and increased market share.

Conclusion

The supply of furosemide is dominated by a handful of large-scale multinational companies complemented by regional manufacturers and CMOs. Their ability to meet global demand hinges on manufacturing capacity, regulatory compliance, raw material availability, and geopolitical stability. Continued industry consolidation, technological innovation, and evolving regulatory landscapes will shape future supply dynamics.

---

Key Takeaways

• Leading global suppliers include Teva, Sandoz, Viatris, and Hikma, each with extensive manufacturing networks.
• Regional manufacturers in Asia and other emerging markets significantly contribute to local and international supplies.
• Regulatory compliance and manufacturing quality assurance are critical factors for sustained supply.
• Supply chain disruptions can arise from raw material shortages, regulatory changes, or geopolitical tensions.
• Industry consolidation and technological advancements are likely to influence future supplier capabilities.

---

FAQs

1. Are there any patent restrictions on furosemide manufacturing currently?
No. Furosemide’s original patents have long expired, allowing widespread generic manufacturing. However, specific formulations or delivery methods may still be protected under newer patents in certain regions.

2. Which regions have the highest production capacity for furosemide?
North America, Europe, and India comprise the largest manufacturing bases, with India emerging as a major center for generic drug production, including furosemide.

3. How do regulatory standards impact supplier qualification?
Suppliers must meet stringent GMP requirements set by authorities like the FDA and EMA. Non-compliance can delay approvals and restrict market access, impacting supply reliability.

4. What is the risk of supply shortages for furosemide?
Risks include raw material shortages, manufacturing disruptions, regulatory hurdles, and geopolitical or trade issues. Diversified sourcing and strategic stockpiles mitigate such risks.

5. Can new players enter the furosemide market easily?
Entry is feasible but requires compliance with international manufacturing standards, regulatory approvals, and established supply chain networks. The high cost of GMP compliance presents barriers for small or new entrants.

---

Sources:

1. [1] Pharmaceutical Technology, "Global Furosemide Market Analysis," 2022.
2. [2] FDA Drug Approvals Database.
3. [3] European Medicines Agency, "List of Approved Active Substances."
4. [4] Company Annual Reports: Teva, Sandoz, Viatris, Hikma.
5. [5] World Health Organization, "Prequalification of Medicines Program."